Ketamine

What Ketamine Is

Ketamine is a dissociative anaesthetic: a synthetic compound that blocks NMDA glutamate receptors, used in human surgery, emergency medicine, and veterinary practice worldwide. It sits awkwardly in a site about psychedelics, because pharmacologically it is not one. It produces a non-ordinary state that overlaps with the psychedelic state at the edges and diverges from it sharply in mechanism, duration, and risk.

What a reader actually encounters depends entirely on the route. In a clinic it is a clear sterile solution, given by infusion or injection, or a nasal spray. Outside one it is almost always a white crystalline powder, produced by evaporating that same pharmaceutical solution, and insufflated. Ketamine is also the only substance covered on this site with an ordinary, above-board medical supply chain, which shapes nearly everything else about it.

It is more useful to think of ketamine as a medicine with a psychedelic-adjacent side than as a psychedelic with a medical use. That framing gets the risks in the right order, and the most important of them, dependence, is one classical psychedelics do not really have.

Where Ketamine Comes From

Ketamine was synthesised in 1962 by Calvin Stevens, a chemist consulting for Parke-Davis, and carried the laboratory designation CI-581. It came directly out of the company's work on phencyclidine. PCP was an effective anaesthetic that left patients agitated, confused, and sometimes psychotic for hours after surgery, and the search was on for a shorter-acting compound in the same class that did the anaesthetic job without the long tail. Ketamine was the result, and its brevity is not incidental to what it is.

There is no plant here and no extraction. Ketamine is made in a lab, and unlike almost everything else covered on this site, it is made lawfully and at scale. It appears on the World Health Organization's Model List of Essential Medicines, which means it is manufactured in industrial quantities for hospitals and veterinary clinics in every part of the world.

Racemic, S, and R

The ketamine molecule is chiral, which means it exists in two mirror-image forms. Ordinary ketamine is racemic: an equal mixture of S(+) ketamine, called esketamine, and R(−) ketamine, called arketamine. Esketamine binds the NMDA receptor more strongly and is the form marketed as Spravato. Arketamine is the quieter one, and early research has asked whether it might carry antidepressant effects with less dissociation. That question is not settled, and nothing sold outside a pharmacy is separated by enantiomer anyway.

How it reaches people outside a clinic

Illicit ketamine comes from two places: diverted pharmaceutical and veterinary stock, and clandestine synthesis, much of it produced in India and China. Diverted product starts as a sterile liquid and has to be dried to a powder, usually by evaporation in a domestic oven or pan. That step is where a lot of the variability comes from, because incomplete drying leaves solvent behind and a damp crystal weighs more than it should. The practical consequence lands in dosing: a gram of poorly dried ketamine is not a gram of ketamine.

The supply picture differs from most substances in one useful way and one dangerous way. The useful part is that material sold as ketamine is often genuinely ketamine, because the legitimate supply is large enough to divert from. The dangerous part is covered in verifying what you have, and it is not adulteration in the usual sense.

History & Cultural Roots

The first human trials ran in 1964 at the University of Michigan, led by Edward Domino and Guenter Corssen. The subjects were prisoners at a Michigan correctional facility, which was unremarkable practice for the period and would not be permissible now. They came out of anaesthesia describing something other than unconsciousness: a sense of being detached from their own bodies and disconnected from the room.

The word for it came from outside the laboratory. Domino described the effect to his wife Toni as the subjects being disconnected from their environment, and she suggested calling it a dissociative anaesthetic. The term stuck well enough that it is still the name of the drug class sixty years later.

The FDA approved ketamine in 1970, and it went into field use almost immediately. It has one property that no other anaesthetic of its era combined: it provides surgical anaesthesia without suppressing breathing or dropping blood pressure. That makes it usable where there is no ventilator, no anaesthetist, and no reliable power, which is why it became standard in battlefield medicine, disaster response, and much of the world's rural surgery.

A separate lineage runs alongside the medical one. The neuroscientist John Lilly experimented on himself extensively with ketamine in the 1970s, and Marcia Moore and Howard Alltounian published an account of their own use in 1978. By the 1990s ketamine had a settled place in club and rave culture, and by the 2000s a reputation there for the dissociation people specifically sought rather than tolerated.

The turn that produced today's clinics came in 2000, when a small controlled study at Yale found that a single sub-anaesthetic infusion lifted depression within hours in patients who had not responded to conventional treatment. Nothing in psychiatry worked on that timescale. The following two decades were largely an effort to replicate the finding, understand it, and build a delivery model around it, ending with the FDA's approval of esketamine as Spravato in 2019.

The scheduling fight

Ketamine is the rare controlled substance that the world decided not to control. Proposals to place it under the UN drug conventions were brought repeatedly, most forcefully in 2015, and were rejected. The opposition came from anaesthesiologists and global health bodies making a straightforward argument: international scheduling would add paperwork and cost to the one anaesthetic that works in places with no infrastructure, and people would die of untreated surgical need. That argument won, and it is the reason ketamine's legal position looks so different from everything else on this site.

Pharmacology: How Ketamine Works

Ketamine's primary mechanism is antagonism of NMDA (N-methyl-D-aspartate) glutamate receptors, a fundamentally different mechanism from classical psychedelics, which act primarily on serotonin 5-HT2A receptors. NMDA receptors are involved in synaptic plasticity, learning, memory, and pain processing. Blocking them produces the dissociative, anaesthetic, and psychedelic-adjacent effects characteristic of ketamine.

The antidepressant mechanism appears to operate through downstream neuroplasticity: ketamine's NMDA antagonism triggers a rapid increase in synaptic AMPA receptor activation, followed by a burst of BDNF (brain-derived neurotrophic factor) release and downstream mTOR signalling, rapidly promoting synaptogenesis (new synaptic connections) in prefrontal circuits that are compromised in depression. This explains ketamine's uniquely rapid antidepressant onset, often within hours, compared to conventional antidepressants that require weeks.

Effects

Ketamine's experiential quality is distinctive. It has more in common with dissociatives like PCP and DXM than with psilocybin or LSD. The signature phenomenon is depersonalisation-derealization: a sense of detachment from one's body, thoughts, and ordinary sense of self, often accompanied by a floating or out-of-body quality.

Low to moderate doses

Relaxation, mild dissociation, dreamy quality, perceptual distortions (particularly visual and auditory). Reduced pain sensitivity. A sense of detachment from worry and rumination that many find temporarily therapeutic.

Higher doses: the "k-hole"

At sufficiently high doses, ketamine produces a state of profound dissociation, complete detachment from the body and ordinary sense of self, with vivid internal experiences that can range from ego-dissolving and transcendent to terrifying. The "k-hole" is unpredictable and can be distressing without appropriate set, setting, and support. Recovery is typically complete within 30–60 minutes of reaching peak.

Duration

Ketamine's psychedelic effects are notably brief compared to classical psychedelics: 45–90 minutes for a moderate dose (intramuscular or intravenous), 20–40 minutes for intranasal. This brevity is clinically valuable, it allows supervised sessions without the 4–8-hour commitment required for psilocybin or LSD.

Dosage and Routes of Administration

Therapeutic protocols typically use IV or IM administration in clinical settings. Intranasal and oral formulations are used in out-of-clinic prescribing contexts. Non-therapeutic recreational use typically involves intranasal administration.

Ketamine vs. Classical Psychedelics

The differences are substantial and matter for understanding therapeutic applications and phenomenological character:

Mechanism. NMDA antagonist (ketamine) vs. 5-HT2A agonist (classical psychedelics). Different receptor systems, different neural networks affected.

Phenomenology. Dissociation, detachment, floating (ketamine) vs. perceptual richness, ecological encounters, emotional depth, ego dissolution (classical psychedelics). Ketamine experiences are generally less likely to produce the relational and ecological phenomenological content that characterises psilocybin and ayahuasca.

Duration. 45–90 minutes (ketamine) vs. 4–12 hours (classical psychedelics). Ketamine is far more clinically manageable.

Dependence potential. Meaningful (ketamine) vs. very low (classical psychedelics). This is among the most important distinctions from a harm reduction perspective.

Legal status. Medically prescribed and regulated (ketamine) vs. Schedule I (most classical psychedelics in most jurisdictions). Ketamine is currently the only route to legal, clinically administered psychedelic-adjacent treatment in most of North America.

Clinical Research on Ketamine

The clinical evidence for ketamine's antidepressant effects is substantial and replicable, arguably stronger in aggregate than psilocybin, simply because research has been ongoing since the 1990s. Multiple meta-analyses confirm rapid, significant antidepressant and anti-suicidal ideation effects in treatment-resistant patients. The challenge is durability: antidepressant effects typically last days to weeks rather than months, and repeated dosing raises tolerance and dependence concerns.

Research on whether the psychedelic experience itself contributes to antidepressant effects (beyond the neuroplasticity mechanism) is ongoing and contested. Some studies suggest the dissociative experience contributes; others suggest the biological mechanism is sufficient. This has direct implications for the role of set, setting, and integration in ketamine therapy.

Risks: Dependence, Bladder, and Cognition

Dependence. Unlike classical psychedelics, ketamine carries genuine dependence potential, both psychological (the dissociative relief it provides can become a sought-after escape) and, with very frequent use, some degree of physical dependence. Daily or near-daily ketamine use has been documented and is associated with serious harm. This risk is primarily relevant in recreational/unmanaged use rather than structured therapeutic contexts.

Ketamine-induced uropathy. Frequent, high-dose ketamine use is associated with severe and potentially irreversible bladder damage, ketamine uropathy. Symptoms include urinary frequency, urgency, pain, and in advanced cases, reduced bladder capacity requiring surgical intervention. This risk is dose- and frequency-dependent. It has been documented primarily in recreational users taking large amounts frequently, but it is a serious harm and a meaningful reason to avoid chronic non-therapeutic use.

Cognitive effects. Heavy ketamine use is associated with impaired memory and cognitive function. Effects appear to be largely reversible with abstinence in moderate users, but may be more persistent in heavy, chronic users.

Dissociation as a risk. For people with a history of dissociative symptoms, PTSD-related derealization, or dissociative disorders, ketamine can reinforce dissociation rather than facilitate healing, without careful therapeutic framing and support.

Verifying What You Have

Ketamine inverts the usual testing problem. With MDMA the danger is that something else has been sold to you under a familiar name, and reagents are reasonably good at catching that. With ketamine the material is frequently genuine, and the thing most likely to hurt you is a close chemical relative that reagents cannot separate from it.

Why reagents are weak here

Ketamine gives little or no colour change with the two reagents most people own, Marquis and Mecke. Mandelin is the one worth having, producing an orange to brown reaction. The difficulty is that ketamine's most characteristic result is an absence of reaction, and an absence of reaction is also what you get from a sample containing nothing your kit tests for. A blank Marquis is consistent with ketamine and consistent with a great many other white powders. Treat reagents here as a way of ruling out an obvious substitution rather than a way of confirming what you have.

The analogues, which are the actual problem

A family of ketamine analogues circulates in the same supply: deschloroketamine (DCK), 2-fluorodeschloroketamine (2-FDCK), and several others. They have been widespread in European and North American supply for years, sometimes sold knowingly and often not. They matter because they are not equivalent. Several are more potent by weight and considerably longer-acting, so a dose measured against your experience of ketamine can produce something much stronger that lasts several times as long. Someone expecting forty minutes can be dissociated for hours.

No home reagent distinguishes these from ketamine. That is the honest position, and it drives the only reliable precautions: treat every new batch as an unknown regardless of source, start at a fraction of your usual amount, and wait long enough to establish the duration before considering anything further. With ketamine specifically, redosing before you know how long a batch lasts is the common route into an unplanned k-hole.

Weight is not purity

Because much illicit ketamine begins as a pharmaceutical solution dried at home, residual solvent is common and it does not announce itself. Damp or clumping crystal weighs more than the ketamine in it, which means the same measured amount from two batches can differ substantially in actual dose. Visibly wet material should be treated as an unknown quantity rather than a known one.

Lab testing

Laboratory analysis is the only method that answers the analogue question. DrugsData accepts anonymous mail-in samples in the United States and publishes results. In-person drug-checking services operate in a growing number of cities and are the better option where they exist. Legal status varies, so check what applies locally before posting anything anywhere.

Legal Status

Ketamine occupies a position no other substance on this site does. It is not scheduled under the UN drug conventions at all, following the rejection of repeated proposals to place it there, so its legal status is set entirely by national law. Everywhere it is controlled, it is controlled as a medicine with accepted use rather than as a prohibited drug.

United States: Schedule III under the Controlled Substances Act since 1999. It is legal to prescribe, and this is where a distinction worth understanding lives. Racemic ketamine is FDA-approved as an anaesthetic and nothing else, which means every psychiatric use of it is off-label prescribing. Only esketamine, as Spravato, carries an approved depression indication, and it is restricted to certified settings under a risk-management programme requiring on-site administration and a period of monitoring afterwards. When a clinic advertises ketamine therapy, it is almost always offering the off-label version.

Canada: Schedule I under the Controlled Drugs and Substances Act, with accepted medical use and ordinary prescribing. Spravato is approved by Health Canada for treatment-resistant depression.

United Kingdom: Class B under the Misuse of Drugs Act, raised from Class C in 2014 following evidence of bladder harm.

Elsewhere: controlled as a prescription medicine in most countries, with penalties for non-medical possession varying widely. Because there is no treaty floor, the variation between jurisdictions is greater than for scheduled psychedelics.

At-home prescribing is the genuinely unsettled area. United States rules normally require an in-person examination before a controlled substance is prescribed, and the exceptions that allowed telehealth ketamine to expand have been extended repeatedly rather than made permanent. This is live regulation that has moved several times, so confirm the current position before relying on any description of it, including this one. See the legal quick reference for how ketamine compares to other substances.

Ketamine Therapy in Practice

Ketamine therapy clinics have expanded rapidly across North America. Provision ranges from rigorous, psychotherapy-integrated protocols to medical spas that administer ketamine infusions with minimal psychological support. The quality of the container matters, the same neuroplasticity-promoting properties that make ketamine effective for depression can consolidate whatever psychological content and relational patterns are active during and after the session.

Thoughtful ketamine therapy includes: careful intake and screening; intentional preparation; supervised administration with supportive presence; immediate post-session integration; and ongoing psychotherapy between sessions. Clinics that offer IV drips with noise-cancelling headphones but no psychological preparation or integration support are providing the pharmacology without the context.

Questions worth asking a clinic

Who screens you, and do they ask about dissociative symptoms and substance-use history rather than depression alone? Is a clinician present for the session or only nearby? What is offered between sessions, and is it included or billed separately? How many sessions does the protocol assume, and what is the plan when the course ends? That last question matters most. Antidepressant effects from ketamine typically last days to weeks, so a clinic without an answer for what happens after the final infusion has left the hardest part of the problem with you.

At-home programmes

Telehealth services that post sublingual ketamine for unsupervised use at home are a different proposition from a supervised infusion, and the differences run in one direction. Nobody is present if the dose lands harder than expected, nobody observes how you respond, and the material sits in your home between sessions, which is precisely the arrangement that makes escalating use easy. These programmes suit people who are stable, screened properly, and honest with themselves about frequency. They suit people using ketamine to get away from something considerably less well.

If You Are Considering This

The general groundwork sits on assessment, preparation, and integration. Four things are specific to ketamine.

The legal route is genuinely available, and usually better

This is the only substance on the site where that sentence is true. If your interest in ketamine is about depression rather than curiosity, a supervised clinical course gives you screening, a known dose, someone present, and a record. None of that is available to you otherwise, and the cost comparison is less lopsided than it looks once repeated unsupervised use enters the picture.

Decide the frequency rule before the first time, not after

Dependence is the ketamine-specific risk, and it is a pattern risk rather than a dose risk. The combination that causes trouble is a short duration, reliable relief from distress, and easy availability. That combination does not feel like a problem at any single point along the way, which is exactly what makes it one. Set a hard ceiling on frequency while the decision is still abstract, treat any use prompted by feeling bad as the line rather than the exception, and read the bladder and cognitive risks before deciding what your ceiling is.

Physical safety matters more than with classical psychedelics

At moderate and higher doses ketamine impairs coordination substantially and nausea is common. Falls and vomiting while dissociated are the realistic injuries, not psychological ones. Be lying down before it comes on rather than after, keep a sober person present, and eat nothing for a few hours beforehand. The combination warning about alcohol, opioids, and benzodiazepines is the one to take literally, because respiratory depression is how ketamine actually kills people.

Some histories make this the wrong substance

If dissociation is already part of how you respond to stress, whether through PTSD-related derealization or a dissociative disorder, ketamine reinforces the pattern you would be trying to work with. This is worth being honest about, because ketamine is unusually good at making that particular problem feel temporarily solved.

Ketamine rewards being treated as a medicine and punishes being treated as an escape. The difference between those two is almost entirely a question of how often, decided in advance.

Frequently Asked Questions